Ozempic label expanded to include reduced risk of worsening kidney disease
The FDA on Tuesday broadened the label of Novo Nordisk’s blockbuster diabetes drug Ozempic.
The GLP-1 injectable can now also be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
